AMRX
Price
$8.42
Change
+$0.05 (+0.60%)
Updated
Jul 3 closing price
Capitalization
1.87B
32 days until earnings call
DVAX
Price
$10.27
Change
+$0.11 (+1.08%)
Updated
Jul 3 closing price
Capitalization
1.62B
25 days until earnings call
Interact to see
Advertisement

AMRX vs DVAX

Header iconAMRX vs DVAX Comparison
Open Charts AMRX vs DVAXBanner chart's image
Amneal Pharmaceuticals
Price$8.42
Change+$0.05 (+0.60%)
Volume$898.79K
Capitalization1.87B
Dynavax Technologies
Price$10.27
Change+$0.11 (+1.08%)
Volume$511.14K
Capitalization1.62B
AMRX vs DVAX Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. DVAX commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and DVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (AMRX: $8.42 vs. DVAX: $10.27)
Brand notoriety: AMRX and DVAX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AMRX: 47% vs. DVAX: 25%
Market capitalization -- AMRX: $1.87B vs. DVAX: $1.62B
AMRX [@Pharmaceuticals: Other] is valued at $1.87B. DVAX’s [@Pharmaceuticals: Other] market capitalization is $1.62B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRX is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 6 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s).

  • AMRX’s TA Score: 6 bullish, 3 bearish.
  • DVAX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, AMRX is a better buy in the short-term than DVAX.

Price Growth

AMRX (@Pharmaceuticals: Other) experienced а +3.57% price change this week, while DVAX (@Pharmaceuticals: Other) price change was +3.32% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

AMRX is expected to report earnings on Aug 07, 2025.

DVAX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($1.87B) has a higher market cap than DVAX($1.62B). AMRX has higher P/E ratio than DVAX: AMRX (90.00) vs DVAX (31.63). AMRX YTD gains are higher at: 6.313 vs. DVAX (-19.577). AMRX has higher annual earnings (EBITDA): 400M vs. DVAX (9.67M). DVAX has more cash in the bank: 742M vs. AMRX (91.5M). DVAX has less debt than AMRX: DVAX (257M) vs AMRX (2.75B). AMRX has higher revenues than DVAX: AMRX (2.39B) vs DVAX (232M).
AMRXDVAXAMRX / DVAX
Capitalization1.87B1.62B115%
EBITDA400M9.67M4,138%
Gain YTD6.313-19.577-32%
P/E Ratio90.0031.63285%
Revenue2.39B232M1,032%
Total Cash91.5M742M12%
Total Debt2.75B257M1,070%
FUNDAMENTALS RATINGS
AMRX vs DVAX: Fundamental Ratings
AMRX
DVAX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
5873
SMR RATING
1..100
9993
PRICE GROWTH RATING
1..100
4663
P/E GROWTH RATING
1..100
2898
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (69) in the Biotechnology industry is in the same range as AMRX (90) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is in the same range as DVAX (73) in the Biotechnology industry. This means that AMRX’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's SMR Rating (93) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as DVAX (63) in the Biotechnology industry. This means that AMRX’s stock grew similarly to DVAX’s over the last 12 months.

AMRX's P/E Growth Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for DVAX (98) in the Biotechnology industry. This means that AMRX’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXDVAX
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
71%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
77%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 20 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
73%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGBEX48.070.66
+1.39%
Principal Blue Chip R3
MBCGX20.800.22
+1.07%
MassMutual Blue Chip Growth A
SUTAX16.450.15
+0.92%
AB Sustainable US Thematic A
NMUEX11.050.10
+0.91%
Neuberger Berman Multi-Cap Opp E
FAMEX60.040.40
+0.67%
FAM Dividend Focus Fund Investor

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.60%
PAHC - AMRX
47%
Loosely correlated
+0.21%
VTRS - AMRX
42%
Loosely correlated
-0.21%
EBS - AMRX
40%
Loosely correlated
-1.69%
AMPH - AMRX
40%
Loosely correlated
-1.61%
ZTS - AMRX
39%
Loosely correlated
+0.06%
More

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ESPR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ESPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+1.08%
ESPR - DVAX
34%
Loosely correlated
+1.74%
SUPN - DVAX
34%
Loosely correlated
-0.28%
ALKS - DVAX
33%
Loosely correlated
-0.52%
AMRX - DVAX
30%
Poorly correlated
+0.60%
AMPH - DVAX
29%
Poorly correlated
-1.61%
More